https://www.biospace.com/marinus-launches-expanded-access-program-for-ganaxolone-treatment-in-cdkl5-deficiency-disorder
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the...
expanded access programmarinuslaunchesganaxolonetreatment